Halozyme Therapeutics, Inc. (BIT:1HALO)
Italy flag Italy · Delayed Price · Currency is EUR
59.64
0.00 (0.00%)
Last updated: Mar 11, 2026, 9:00 AM CET

Halozyme Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
133.82115.85118.37234.2118.72
Short-Term Investments
9480.22217.63128.6622.2
Cash & Short-Term Investments
142.82596.07336362.79740.92
Cash Growth
-76.04%77.40%-7.38%-51.03%101.33%
Accounts Receivable
441.27308.46234.21231.0790.98
Inventory
176.48141.86127.6100.1253.91
Other Current Assets
64.6438.9548.6145.0240.48
Total Current Assets
825.211,085746.42739.01926.29
Net Property, Plant & Equipment
82.1475.0474.9475.578.79
Other Intangible Assets
981.47401.83472.88546.65-
Goodwill
580.36416.82416.82409.05-
Other Long-Term Assets
56.1584.4522.271.23169.35
Total Assets
2,5252,0631,7331,8421,104
Accounts Payable
20.910.2511.8217.691.54
Accrued Expenses
156.19128.85100.6899.7624.44
Current Portion of Long-Term Debt
---13.3389.42
Unearned Revenue
----1.75
Total Current Liabilities
177.09139.1112.49130.79117.15
Long-Term Debt
2,1431,5061,4991,493787.26
Other Long-Term Liabilities
156.7954.7637.7248.163.07
Total Long-Term Liabilities
2,2991,5611,5371,541790.33
Total Liabilities
2,4771,7001,6491,672907.48
Common Stock
0.120.120.130.140.14
Additional Paid-in Capital
12-2.4127.37256.35
Accumulated Other Comprehensive Income
-18.093.83-9.28-0.92-0.62
Retained Earnings
54.79359.8790.55143.22-58.91
Shareholders' Equity
48.81363.8283.81169.8196.95
Total Liabilities & Equity
2,5252,0631,7331,8421,104
Total Debt
2,1431,5061,4991,506876.67
Net Cash (Debt)
-2,000-909.72-1,163-1,143-135.75
Net Cash Per Share
-16.14-7.03-8.67-8.13-0.93
Book Value
48.81363.8283.81169.8196.95
Book Value Per Share
0.392.810.621.211.34
Tangible Book Value
-1,513-454.83-805.89-785.9196.95
Tangible Book Value Per Share
-12.21-3.51-6.01-5.591.34
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.